tokens: PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ). PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ), in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ), every 3 weeks until disease progression or unacceptable toxicity .